Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation.

Puig-Basagoiti F, Fukuhara T, Tamura T, Ono C, Uemura K, Kawachi Y, Yamamoto S, Mori H, Kurihara T, Okamoto T, Aizaki H, Matsuura Y.

J Virol. 2016 Sep 12;90(19):8464-77. doi: 10.1128/JVI.00471-16. Print 2016 Oct 1.

2.

Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus.

Fukuhara T, Ono C, Puig-Basagoiti F, Matsuura Y.

Trends Microbiol. 2015 Oct;23(10):618-629. doi: 10.1016/j.tim.2015.07.007. Review.

PMID:
26433694
3.

Identification and characterization of inhibitors of West Nile virus.

Puig-Basagoiti F, Qing M, Dong H, Zhang B, Zou G, Yuan Z, Shi PY.

Antiviral Res. 2009 Jul;83(1):71-9. doi: 10.1016/j.antiviral.2009.03.005. Epub 2009 Apr 1.

4.

A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor.

Zou G, Puig-Basagoiti F, Zhang B, Qing M, Chen L, Pankiewicz KW, Felczak K, Yuan Z, Shi PY.

Virology. 2009 Feb 5;384(1):242-52. doi: 10.1016/j.virol.2008.11.003. Epub 2008 Dec 5.

5.

West Nile virus infection of Drosophila melanogaster induces a protective RNAi response.

Chotkowski HL, Ciota AT, Jia Y, Puig-Basagoiti F, Kramer LD, Shi PY, Glaser RL.

Virology. 2008 Jul 20;377(1):197-206. doi: 10.1016/j.virol.2008.04.021. Epub 2008 May 23.

6.

West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism.

Dong H, Ren S, Zhang B, Zhou Y, Puig-Basagoiti F, Li H, Shi PY.

J Virol. 2008 May;82(9):4295-307. doi: 10.1128/JVI.02202-07. Epub 2008 Feb 27.

7.

Distinct RNA elements confer specificity to flavivirus RNA cap methylation events.

Dong H, Ray D, Ren S, Zhang B, Puig-Basagoiti F, Takagi Y, Ho CK, Li H, Shi PY.

J Virol. 2007 May;81(9):4412-21. Epub 2007 Feb 14.

8.

A mouse cell-adapted NS4B mutation attenuates West Nile virus RNA synthesis.

Puig-Basagoiti F, Tilgner M, Bennett CJ, Zhou Y, Muñoz-Jordán JL, García-Sastre A, Bernard KA, Shi PY.

Virology. 2007 Apr 25;361(1):229-41. Epub 2006 Dec 18.

9.

Triaryl pyrazoline compound inhibits flavivirus RNA replication.

Puig-Basagoiti F, Tilgner M, Forshey BM, Philpott SM, Espina NG, Wentworth DE, Goebel SJ, Masters PS, Falgout B, Ren P, Ferguson DM, Shi PY.

Antimicrob Agents Chemother. 2006 Apr;50(4):1320-9.

10.

Identification of compounds with anti-West Nile Virus activity.

Goodell JR, Puig-Basagoiti F, Forshey BM, Shi PY, Ferguson DM.

J Med Chem. 2006 Mar 23;49(6):2127-37.

PMID:
16539402
11.

High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery.

Puig-Basagoiti F, Deas TS, Ren P, Tilgner M, Ferguson DM, Shi PY.

Antimicrob Agents Chemother. 2005 Dec;49(12):4980-8.

12.

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.

Puig-Basagoiti F, Forns X, Furcić I, Ampurdanés S, Giménez-Barcons M, Franco S, Sánchez-Tapias JM, Saiz JC.

J Gen Virol. 2005 Apr;86(Pt 4):1067-75.

PMID:
15784900
13.

Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease.

Franco S, Giménez-Barcons M, Puig-Basagoiti F, Furcic I, Sánchez-Tapias JM, Rodés J, Sáiz JC.

J Med Virol. 2003 Oct;71(2):195-204.

PMID:
12938193
14.

Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission.

Tàpia N, Franco S, Puig-Basagoiti F, Menéndez C, Alonso PL, Mshinda H, Clotet B, Saiz JC, Martínez MA.

J Gen Virol. 2003 Mar;84(Pt 3):607-13.

PMID:
12604812
15.

[Subgenomic replications of hepatitis C virus (HCV): new possibilities for hepatitis C prophylaxis and treatment].

Puig-Basagoiti F, Sáiz JC.

Gastroenterol Hepatol. 2001 Dec;24(10):506-10. Review. Spanish. No abstract available.

PMID:
11730621
16.

Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation.

Sánchez-Fueyo A, Giménez-Barcons M, Puig-Basagoiti F, Rimola A, Sánchez-Tapias JM, Sáiz JC, Rodés J.

J Med Virol. 2001 Oct;65(2):266-75.

PMID:
11536232
17.

Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.

Puig-Basagoiti F, Sáiz JC, Forns X, Ampurdanès S, Giménez-Barcons M, Franco S, Sánchez-Fueyo A, Costa J, Sánchez-Tapias JM, Rodés J.

J Med Virol. 2001 Sep;65(1):35-44.

PMID:
11505441
18.

High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.

Giménez-Barcons M, Franco S, Suárez Y, Forns X, Ampurdanès S, Puig-Basagoiti F, Sánchez-Fueyo A, Barrera JM, Llovet JM, Bruix J, Sánchez-Tapias JM, Rodés J, Saiz JC.

Hepatology. 2001 Jul;34(1):158-67.

PMID:
11431747
19.

Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressure.

Giménez-Barcons M, Sánchez-Fueyo A, Ampurdanés S, Puig-Basagoiti F, Guilera M, Ibáñez A, Clotet B, Martínez MA, Rodés J, Saiz JC, Sánchez-Tapias JM.

Antiviral Res. 2000 May;46(2):157-70.

PMID:
10854667
20.

Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV.

Puig-Basagoiti F, Cabana M, Guilera M, Giménez-Barcons M, Sirera G, Tural C, Clotet B, Sánchez-Tapias JM, Rodés J, Saiz JC, Martínez MA.

J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):89-94.

PMID:
10708061

Supplemental Content

Loading ...
Support Center